Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which …
| Métrica | KZIA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | -49290.5% | -32.5% | -49258.0% |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | -341.6% | -30.9% | -310.6% |
| Current Ratio | 0.35 | 2.73 | -2.38 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -341.6% | — |
| ✗Flujo de caja operativo positivo | −A$13M | −A$10M |
| ✗Rentabilidad sobre activos al alza | -341.6% | -124.1% |
| ✓Caja operativa/activos supera al ROA | -219.1% | ROA -341.6% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 0.35 | 0.24 |
| ✗Sin aumentar el nº de acciones | 548M | 264M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.01 | 0.11 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 17442.9% |
KAZIA THERAPEUTICS LTD cotiza a 7.25 USD y tiene una capitalización bursátil de $83M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud